 new anticancer drug delivery system management carcinomatous peritonitis new drug delivery system treatment carcinomatous peritonitis poly L-microcapsules organic phase separation technique drug-releasing capacities anticancer effects microcapsules vitro dissolvable polymolecular poly L-lactic acid microns diameter content weight/weight time microcapsules hours vitro hours vivo release poly L-lactic acid peritoneal cavity caused side effects equivalent dose solution addition macroscopic microscopic examinations various abdominal organs toxic effects microcapsules administration abdominal cavity rats carcinomatous peritonitis concentration high level extended period ascites low levels plasma conclusion present studies effective life tumor-bearing hosts systemic side effects solution